老年卵巢癌患者的新辅助化疗:使用率与有效性
基于SEER-Medicare数据库纳入2000至2013年≥66岁、III-IV期上皮性卵巢癌接受手术和铂类/紫杉类化疗的患者,22.5%接受新辅助化疗,使用率从2000年16%升至2013年35.4%(p < .0001);倾向评分匹配后,III期患者初次肿瘤细胞减灭术(PCS)中位总生存长于新辅助化疗(38.8 vs 28个月,p ≤ .0001),IV期及>80岁患者两组无生存差异。
要点
- 老年卵巢癌新辅助化疗使用率从2000年16%增至2013年35.4%(p < .0001)。
- 接受PCS者造口率高于新辅助化疗(23.3% vs 10.8%,p < .0001)。
- III期患者PCS中位总生存长于新辅助化疗(38.8 vs 28个月,p ≤ .0001)。
核心结论
- 老年患者接受PCS前应审慎考虑;IV期患者两种治疗生存结局相似,但新辅助化疗围手术期并发症低于PCS;III期患者PCS与总生存改善相关,但围手术期并发症和急性照护更高。
研究设计与样本
- 基于SEER-Medicare数据库的人群队列研究,纳入2000至2013年诊断、≥66岁、III-IV期上皮性卵巢癌接受手术和铂类/紫杉类化疗作为初始治疗的患者,采用倾向评分匹配分析结局,Kaplan-Meier分析比较匹配队列总生存。
主要发现
- 2000至2013年22.5%的老年女性接受新辅助化疗,使用率从2000年16%上升至2013年35.4%(p < .0001)。
- 接受PCS者造口创建率高于新辅助化疗(23.3% vs 10.8%,p < .0001),且无论分期,PCS者感染和其他手术并发症更高。
- III期卵巢癌接受PCS者中位总生存长于新辅助化疗(38.8 vs 28个月,p ≤ .0001)。
- IV期患者新辅助化疗与PCS无生存差异(29.4 vs 29.8个月,p = .61),>80岁女性亦无生存差异。
临床怎么用
- 作者认为老年患者接受PCS前应审慎考虑;IV期患者生存结局相似而新辅助化疗围手术期并发症更低,III期患者PCS与总生存改善相关但围手术期并发症和急性照护更高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemotherapy (NACT) may reduce perioperative morbidity in women undergoing primary treatment for ovarian cancer. We evaluated patterns of use and outcomes in a population-based cohort of elderly women with ovarian cancer (OC). METHODS: A cohort of patients ≥66 years old diagnosed between 2000 and 2013 with stage III-IV epithelial OC who received surgery and platinum/taxane chemotherapy for primary treatment was identified from the SEER-Medicare database. Propensity-score matching methods were used to examine differences in outcomes. Kaplan-Meier analysis was performed to compare overall survival (OS) in the matched cohort. RESULTS: From 2000 to 2013, 22.5% of older women received NACT. The use of NACT increased over time from 16% in 2000 to 35.4% in 2013 (p < .0001). Among women who received PCS, the rate of ostomy creation was higher compared with NACT (23.3% vs. 10.8%, p < .0001). Infectious and other surgical complications were higher among those who had PCS, regardless of stage. Median OS of women III ovarian cancer who underwent PCS was longer compared with NACT (38.8 vs. 28 months, p ≤ .0001). There were no survival differences between NACT and PCS in women with stage IV disease (29.4 vs. 29.8 months, p = .61) or for women aged >80. CONCLUSION: Careful consideration should be given to older patients prior to undergoing PCS. Survival outcomes were similar for patients with stage IV disease, although NACT was associated with decreased perioperative morbidity compared with PCS. Among women with stage III disease, PCS was associated with improved overall survival, but higher rates of perioperative morbidity and acute care.
引用
- Meyer LA, He W, Sun CC, et al. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. Gynecol Oncol. 2018. PMID: 29961559. doi:10.1016/j.ygyno.2018.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。